Balversa (erdafitinib tablets – Janssen) — Cigna
Pancreatic Adenocarcinoma
Initial criteria
- Patient is age ≥ 18 years
- Patient has a fibroblast growth factor receptor (FGFR) genetic alterations
- Patient has locally advanced, recurrent, or metastatic disease
- Medication is used for subsequent therapy
- Medication is used as a single agent
Approval duration
1 year